Hematology

Pharmacists play a crucial role in optimizing CAR-T therapy outcomes by guiding bridging therapy decisions and enhancing patient safety through proactive collaboration.

Pharmacists can contribute to the care of patients with multiple myeloma by managing cytokine release syndrome and encouraging vaccination when receiving anti-CD38 antibody treatment.

New research reveals that effective bridging therapy before cilta-cel infusion significantly enhances safety and long-term outcomes in patients with multiple myeloma.

In an analysis of the intention-to-treat population of the BENEFIT study, investigators demonstrated improved sustained minimal residual disease negativity with the Isa-VRd regimen in newly diagnosed multiple myeloma (NDMM).

Experts at the ASH Annual Meeting and Exposition in Orlando, Florida, explored innovative strategies and treatments for improving outcomes in diffuse large B-cell lymphoma.

The American Society of Hematology (ASH) Annual Meeting and Exposition will feature the latest news, clinical trial updates, and key opinion leaders in the hematology field.

Breyanzi becomes the first FDA-approved CAR-T therapy for relapsed marginal zone lymphoma, offering hope with impressive response rates and durable outcomes.

MRD and ctDNA testing could revolutionize monitoring and diagnosing precursor diseases of multiple myeloma.

High-dose busulfan-melphalan enhances VRd therapy, improving progression-free survival in high-risk multiple myeloma patients undergoing ASCT.

Mount Sinai's study uncovers how ciltacabtagene autoleucel enhances long-term remission in multiple myeloma by leveraging the patient's immune response.

Ziftomenib gains FDA approval as a targeted treatment for relapsed acute myeloid leukemia with NPM1 mutations, offering new hope for patients.

Talquetamab shows promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma, reinforcing its role in advanced treatment strategies.

Leukogene's M2T-CD33 gains FDA orphan drug status, promising a novel immunotherapy approach for acute myeloid leukemia treatment.

CAR-T and BsAb therapies revolutionize multiple myeloma treatment but pose infection risks, necessitating vigilant monitoring and tailored prevention strategies.

RSV infections in multiple myeloma patients delay treatment but do not increase mortality, highlighting the need for further research on infection management.

Expert shares notable findings presented at the 2025 IMS Annual Meeting.

Revumenib was approved for adults and pediatric patients 1 year and older with relapsed or refractory acute myeloid leukemia.

The move emphasizes the need for vigilant monitoring.

Medicaid expansion enhances 5-year cancer survival rates in rural and high-poverty areas, highlighting the importance of financial support for better health outcomes.

Frail patients with multiple myeloma (MM) can safely reduce dexamethasone use, enhancing treatment outcomes without increasing infection risks.

Cevostamab shows promise as a post-CAR T therapy for relapsed/refractory multiple myeloma, enhancing MRD-negative responses and improving patient outcomes.

Etentamig shows promise in managing infections for relapsed/refractory multiple myeloma.

Anitocabtagene autoleucel shows impressive efficacy and safety in treating relapsed/refractory multiple myeloma, achieving a 97% overall response rate.

New IMWG/IMS guidelines enhance risk assessment for multiple myeloma, revealing daratumumab's impact on patient outcomes in real-world settings.